Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and … Read more
Annexin Pharmaceuticals AB (ANNX) - Total Liabilities
Latest total liabilities as of December 2025: Skr5.22 Million SEK
Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.22 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Annexin Pharmaceuticals AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Annexin Pharmaceuticals AB Competitors by Total Liabilities
The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cauldron Energy Limited
PINK:CAULF
|
USA | $1.01 Million |
|
Tarena International Inc
NASDAQ:TCTM
|
USA | $1.90 Billion |
|
Moment Group AB
ST:MOMENT
|
Sweden | Skr893.00 Million |
|
HPP Holdings Bhd
KLSE:0228
|
Malaysia | RM31.62 Million |
|
Verb Technology Company Inc
NASDAQ:VERB
|
USA | $22.42 Million |
|
Royal Helium Ltd
OTCQB:RHCCF
|
USA | $38.96 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)
The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr5.22 Million | -1.86% |
| 2024-12-31 | Skr5.32 Million | -33.04% |
| 2023-12-31 | Skr7.95 Million | +21.81% |
| 2022-12-31 | Skr6.53 Million | +7.71% |
| 2021-12-31 | Skr6.06 Million | +34.05% |
| 2020-12-31 | Skr4.52 Million | -0.59% |
| 2019-12-31 | Skr4.55 Million | -26.52% |
| 2018-12-31 | Skr6.19 Million | -3.45% |
| 2017-12-31 | Skr6.41 Million | -18.72% |
| 2016-12-31 | Skr7.88 Million | +140.18% |
| 2015-12-31 | Skr3.28 Million | +234.61% |
| 2014-12-31 | Skr981.14K | -- |